Rheumatology News This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the most recent publications within this specialty of the MedWorm directory. This is page number 5.

Scientists ID New Genetic Connection for Gout
Title: Scientists ID New Genetic Connection for GoutCategory: Health NewsCreated: 12/28/2012 6:36:00 PMLast Editorial Review: 12/31/2012 12:00:00 AM
Source: MedicineNet Arthritis General - December 31, 2012 Category: Rheumatology Source Type: news

'I am a teenager with arthritis'
'Arthritis was so painful I couldn't sit my exams'
Source: BBC News | Health | UK Edition - December 30, 2012 Category: Consumer Health News Source Type: news

FDA warns of Reumofan Plus sold as 'WOW'
WASHINGTON, Dec. 29 (UPI) -- U.S. health officials say the dietary supplement "WOW" -- marketed as a treatment for arthritis and muscle pain -- is potentially harmful.
Source: Health News - UPI.com - December 29, 2012 Category: Consumer Health News Source Type: news

FDA Advisory Committee Makes Recommendations on Ampligen for Chronic Fatigue Syndrome
PHILADELPHIA, Dec. 21, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (the "Company" or "Hemispherx") today announced the outcome of the meeting of the Arthritis Advisory Committee (the "AAC") of the U.S. Food and Drug Administration (the...
Source: Drugs.com - New Drug Applications - December 27, 2012 Category: Drugs & Pharmacology Source Type: news

Fibromyalgia Underdiagnosed, Report Mayo Clinic ExpertsFibromyalgia Underdiagnosed, Report Mayo Clinic Experts
Many fibromyalgia cases may be undiagnosed, according to a comparison of population-based data for prevalence of diagnosed fibromyalgia with a random population survey. Medscape Medical News
Source: Medscape Today Headlines - December 26, 2012 Category: Consumer Health News Tags: Rheumatology News Source Type: news

New Treatment Strategies in Large-vessel VasculitisNew Treatment Strategies in Large-vessel Vasculitis
Will biologics have a place in the treatment of large-vessel vasculitis? Current Opinion in Rheumatology
Source: Medscape Today Headlines - December 25, 2012 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

UCB gets Japan clearance for neuro and arthritis drugs
BRUSSELS (Reuters) - Belgian pharmaceutical company UCB has secured two regulatory clearances in Japan.
Source: Modern Medicine - December 25, 2012 Category: Journals (General) Source Type: news

Anakinra Effect Ongoing in Adult Onset Still's DiseaseAnakinra Effect Ongoing in Adult Onset Still's Disease
The dramatic efficacy of the IL-1 receptor antagonist anakinra in adult-onset Still's diseases is maintained over the long term, according to researchers. Reuters Health Information
Source: Medscape Medical News Headlines - December 24, 2012 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Holiday Message from Dr. Shiel
Title: Holiday Message from Dr. ShielCategory: Doctor's ViewsCreated: 12/5/2002 12:00:00 AMLast Editorial Review: 12/24/2012 12:00:00 AM
Source: MedicineNet Arthritis General - December 24, 2012 Category: Rheumatology Source Type: news

MHRA to approve ibuprofen/famotidine (Duexis®) pending review of updated licensing documents
Source: BioSpace Area: News According to a BioSpace report, the MHRA will grant a Marketing Authorisation (MA) for Duexis® (ibuprofen/famotidine), pending review of updated licensing documents provided by the company (Horizon Pharma, Inc). This follows a favourable recommendation from the Commission on Human Medicines. Duexis® is intended for the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing upper gastrointestinal ulcers. Clinical trials of this product (controlled data available for up to six months) primarily enrolled patients less than 65 years of...
Source: NeLM - News - December 24, 2012 Category: Drugs & Pharmacology Source Type: news

Clinical Trials in Rheumatology(Mueller et al.)
Source: Springer Medicine titles - December 22, 2012 Category: Databases & Libraries Tags: Internal Medicine Source Type: news

Rintatolimod for Chronic Fatigue Gets FDA Panel's 'No' VoteRintatolimod for Chronic Fatigue Gets FDA Panel's 'No' Vote
A majority of the panel asked for at least 1 additional randomized controlled trial before rintatolimod approval. Medscape Medical News
Source: Medscape Today Headlines - December 21, 2012 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Aggressive, Early Treatment for Rheumatoid Arthritis Reduces Risk of Disability
The risk of disability from rheumatoid arthritis can be dramatically reduced when drugs that modify the immune system are started soon after the disease begins, according to the December issue of Mayo Clinic Health Letter.
Source: Mayo Clinic Health Information - December 21, 2012 Category: Consumer Health Advice Authors: Mayo Clinic Source Type: news

Rub-on pain relievers offer kinder, gentler relief from arthritis pain
When joint pain cries out for relief but ibuprofen and other over-the-counter medicines upset the stomach, it may be worth trying a gentler alternative: anti-inflammatory pain relievers applied to the skin, not taken as a pill, reports the January 2013 issue of the Harvard Men's Health Watch. Pain relievers applied to the skin are called topical analgesics. Prescription versions, which usually deliver nonsteroidal anti-inflammatory drugs (NSAIDs), come as creams, sprays, gels, or patches. The active ingredient soaks in through the skin to reach the pain. In contrast, oral pain relievers flood the whole body with the medica...
Source: New Harvard Health Information - December 21, 2012 Category: Consumer Health Advice Source Type: news

Systemic JIA: 2 Biologicals Succeed in Phase 3 TrialsSystemic JIA: 2 Biologicals Succeed in Phase 3 Trials
Tocilizumab and canakinumab were effective for more than 80% of patients with systemic juvenile idiopathic arthritis in pivotal phase 3 studies. Medscape Medical News
Source: Medscape Today Headlines - December 20, 2012 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Drugs Hold Promise for Severe Juvenile Arthritis Patients
Title: Drugs Hold Promise for Severe Juvenile Arthritis PatientsCategory: Health NewsCreated: 12/19/2012 6:36:00 PMLast Editorial Review: 12/20/2012 12:00:00 AM
Source: MedicineNet Arthritis General - December 20, 2012 Category: Rheumatology Source Type: news

RCTs of canakinumab in systemic juvenile idiopathic arthritis
Source: N Engl J Med Area: News Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis (JIA). Canakinumab is a selective, fully human, anti-interleukin-1? monoclonal antibody that has been assessed in two parallel phase III trials of patients (aged 2 to 19 years) with systemic JIA and active systemic features ((fever; ?2 active joints; C-reactive protein, >30 mg/L; and glucocorticoid dose, ?1.0 mg/kg/d). The studies were conduced at 63 centres that were members of the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Gr...
Source: NeLM - News - December 20, 2012 Category: Drugs & Pharmacology Source Type: news

RCT: Tocilizumab in systemic juvenile idiopathic arthritis
Source: N Engl J Med Area: News Systemic juvenile idiopathic arthritis (JIA) is the most severe subtype of JIA for which treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA. Tocilizumab is an anti-interleukin-6 receptor antibody which has been evaluated in a study of 112 children, 2 to 17 years of age, with active systemic JIA (duration ?6 months and inadequate responses to NSAIDs and glucocorticoids). The participants were randomised to receive tocilizumab (8 mg/kg if weight ?30 kg or 12 mg/kg if weight <30 kg, n= 75) or placebo (n= 37), given intravenously every 2 weeks du...
Source: NeLM - News - December 20, 2012 Category: Drugs & Pharmacology Source Type: news

Reumofan Plus Dietary Supplement Relabeled and Sold as “WOW”: Public Warning - Undeclared Drug Ingredients
The product is being marketed to treat arthritis, muscle pain, osteoporosis, bone cancer, and other conditions; laboratory analysis confirmed "WOW" contains prescription drug ingredients that have the potential to cause serious injury.
Source: FDA MedWatch - December 19, 2012 Category: American Health Source Type: news

New Drugs Offer Hope for Kids with Arthritis (CME/CE)
(MedPage Today) -- A greater understanding of the inflammatory processes underlying systemic juvenile idiopathic arthritis (JIA) has opened the door to significantly more effective treatments, international randomized studies have shown.
Source: MedPage Today Pediatrics - December 19, 2012 Category: Pediatrics Source Type: news

Ceramic-on-ceramic hips good option for juvenile arthritis
Study results suggest that ceramic-on-ceramic artificial hip joints offer a better medium-term prognosis than metal- or ceramic-on-polyethylene joints for children with juvenile idiopathic arthritis.
Source: MedWire News - Bone Health - December 19, 2012 Category: Orthopaedics Source Type: news

Aspergillus fumigatus empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole
Lodge BA, Ashley ED, Steele MP, Perfect JR
Source: The Aspergillus Website - articles - December 19, 2012 Category: Respiratory Medicine Source Type: news

Scientists establish link between inflammatory process and progression of Alzheimer's disease
Researchers have shown that a well-known inflammatory process plays an important role in Alzheimer's disease. This process, which results in the mature production of the pro-inflammatory cytokine called interleukin-1 beta and is involved in the body's defense against infection, has also been established as a clinical target for rheumatoid arthritis. The finding points to the possibility that drugs that disrupt IL-1B may also prove beneficial for patients with Alzheimer's.
Source: ScienceDaily Headlines - December 19, 2012 Category: Science Source Type: news

Interleukin inhibitors effective in refractory severe juvenile arthritis
NEW YORK (Reuters Health) - Italian researchers say two interleukin inhibitors appear to be effective in severe systemic juvenile idiopathic (JIA) arthritis that doesn't respond to standard therapy.
Source: Modern Medicine - December 19, 2012 Category: Journals (General) Source Type: news

The Evolution of Ultrasound in RheumatologyThe Evolution of Ultrasound in Rheumatology
Learn more on the recent advances in musculoskeletal ultrasound and its application in rheumatology. Therapeutic Advances in Musculoskeletal Disease
Source: Medscape Today Headlines - December 18, 2012 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Oral Steroids Increase MI Risk in Rheumatoid ArthritisOral Steroids Increase MI Risk in Rheumatoid Arthritis
The risk for myocardial infarction for patients with rheumatoid arthritis increased with both current dosage of and cumulative exposure to oral glucocorticoids. Medscape Medical News
Source: Medscape Today Headlines - December 18, 2012 Category: Consumer Health News Tags: Rheumatology News Source Type: news

ACPA Positivity and Outcomes in Palindromic RheumatismACPA Positivity and Outcomes in Palindromic Rheumatism
What is the meaning of anticitrullinated peptide/protein antibodies in the sera of patients with palindromic rheumatism? Medscape Rheumatology
Source: Medscape Today Headlines - December 18, 2012 Category: Consumer Health News Tags: Rheumatology Viewpoint Source Type: news

Academic Rheumatology Unit celebrates 25th anniversary
Staff and patients at the Academic Rheumatology Unit recently celebrated a quarter of a century of clinical care, teaching and research.
Source: University of Bristol news - December 18, 2012 Category: Universities & Medical Training Authors: news_text Tags: Other news Source Type: news

Complexities of human disease targeted with $16 million in funding
(Walter and Eliza Hall Institute) Scientists at the Walter and Eliza Hall Institute in Melbourne, Australia, have received more than $16 million in Australian Government funding to pursue research into cancer, malaria, rheumatoid arthritis and the immune system, it was announced today.
Source: EurekAlert! - Medicine and Health - December 18, 2012 Category: Global & Universal Source Type: news

Gout ManagementGout Management
There's been a recent burst of activity in drug development for the treatment of gout. What's new and what's in the pipeline? Therapeutic Advances in Chronic Disease
Source: Medscape Today Headlines - December 16, 2012 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Eli Lilly terminates FLEX-M rheumatoid arthritis study of tabalumab
Eli Lilly and Company has announced the termination of one of three Phase III rheumatoid arthritis registration studies, FLEX-M, for tabalumab.
Source: Drug Development Technology - December 16, 2012 Category: Pharmaceuticals Source Type: news

Etanercept for Psoriatic Arthritis With Recurrent LymphomaEtanercept for Psoriatic Arthritis With Recurrent Lymphoma
Does the use of TNF inhibitors for psoriatic arthritis increase the risk for recurrence of previously treated lymphoma? Journal of Clinical Rheumatology
Source: Medscape Today Headlines - December 14, 2012 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Astrazeneca Announces Top-Line Results Of OSKIRA-4 Phase IIb Study Of Fostamatinib As A Monotherapy For Rheumatoid Arthritis
AstraZeneca recently announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with selectivity for SYK (spleen tyrosine kinase) in development as an oral treatment for rheumatoid arthritis (RA).
Source: Pharmaceutical Online News - December 13, 2012 Category: Pharmaceuticals Source Type: news

Eli Lilly ends rheumatoid arthritis trial due to lack of efficacy
Eli Lilly has announced it plans to halt one of three Phase III drug trials for rheumatoid arthritis drug tabalumab due to insufficient efficacy.
Source: Pharmaceutical Technology - December 13, 2012 Category: Pharmaceuticals Source Type: news

Dark Ages scourge enlightens modern struggle between humans and microbes
New discoveries help explain how the stealthy agent of Black Death avoids tripping a self-destruct mechanism inside germ-destroying cells. The host defense mechanism pyroptosis ("going up in flames") eliminates places for the germs to reproduce and signals the recruitment of disease-fighting cells. Specifically, the findings may hold ideas for biodefense vaccines against plague, and more generally offer clues to controlling excessive inflammatory responses in arthritis, heart and lung diseases, colitis and autoimmune disorders.
Source: ScienceDaily Headlines - December 13, 2012 Category: Science Source Type: news

Trials of New RA Drugs Disappoint
(MedPage Today) -- Two investigational agents once considered promising as treatments for rheumatoid arthritis have shown disappointing results in some clinical trials, although the development programs are continuing.
Source: MedPage Today Geriatrics - December 13, 2012 Category: Geriatrics Source Type: news

Belimumab Revisited: How Has It Performed?Belimumab Revisited: How Has It Performed?
Approved for more than a year now, how has belimumab performed in the clinic, and is there hope for a subcutaneous formulation? Medscape Rheumatology
Source: Medscape Today Headlines - December 13, 2012 Category: Consumer Health News Tags: Rheumatology Commentary Source Type: news

Hopes fade for AstraZeneca and Rigel's arthritis pill
LONDON (Reuters) - An experimental rheumatoid arthritis drug from AstraZeneca proved inferior to Abbott Laboratories' Humira in a clinical study, knocking hopes for one of the few late-stage products in the company's pipeline.
Source: Reuters: Health - December 13, 2012 Category: Consumer Health News Tags: healthNews Source Type: news

Vertebral Fracture Risk in Ankylosing SpondylitisVertebral Fracture Risk in Ankylosing Spondylitis
Vertebral fractures are underdiagnosed in ankylosing spondylitis. Could bone mineral density aid in the assessment of risk? Medscape Rheumatology
Source: Medscape Today Headlines - December 13, 2012 Category: Consumer Health News Tags: Rheumatology Viewpoint Source Type: news

Lilly stops rheumatoid arthritis trial for lack of efficacy
(Reuters) - Eli Lilly and Co said it will stop one of three late-stage trials of its rheumatoid arthritis (RA) drug tabalumab due to insufficient efficacy.
Source: Reuters: Health - December 13, 2012 Category: Consumer Health News Tags: healthNews Source Type: news

Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
FLEX-M study did not meet efficacy expectations in an interim futility analysis; discontinuation not based on safety concerns INDIANAPOLIS, Dec. 13, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will stop...
Source: Drugs.com - Pharma News - December 13, 2012 Category: Pharmaceuticals Source Type: news

AstraZeneca arthritis drug lags Abbott's Humira in test
LONDON (Reuters) - An experimental rheumatoid arthritis drug from AstraZeneca proved inferior to Abbott Laboratories' Humira in a clinical study, knocking hopes for one of the few late-stage products in the company's pipeline.
Source: Reuters: Health - December 13, 2012 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca arthritis drug worse than Humira in study
LONDON (Reuters) - An experimental rheumatoid arthritis drug from AstraZeneca proved inferior to Abbott Laboratories' Humira in a clinical study, knocking hopes for one of the few late-stage products in the company's pipeline.
Source: Reuters: Health - December 13, 2012 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca arthritis drug lags Abbott's Humira in test
LONDON (Reuters) - An experimental rheumatoid arthritis drug from AstraZeneca proved inferior to Abbott Laboratories' Humira in a clinical study.
Source: Modern Medicine - December 13, 2012 Category: Journals (General) Source Type: news

Is methotrexate associated with an increased risk of leukaemia?
Source: Regional Drug and Therapeutics Centre Area: Evidence > Medicines Q & A Methotrexate is classed as an anti-metabolite, which acts through inhibition of dihydrofolate reductase, causing disruption of the folic acid cycle and interference of DNA synthesis and repair. It is licensed for use as treatment in a wide range of neoplastic conditions, including acute leukaemias. It is also licensed for treatment of rheumatoid arthritis and severe, uncontrolled psoriasis There is no compelling, good quality evidence to suggest an increase in leukaemia risk is associated with methotrexate therapy. Patients with autoimmun...
Source: NeLM - Medicines Q and A - December 13, 2012 Category: Drugs & Pharmacology Source Type: news

Dark Ages scourge enlightens modern struggle between man and microbes
(University of Washington) New discoveries reported this week help explain how the stealthy agent of Black Death avoids tripping a self-destruct mechanism inside germ-destroying cells. The host defense mechanism pyroptosis ("going up in flames") eliminates places for the germs to reproduce and signals the recruitment of disease-fighting cells. Specifically, the findings may hold ideas for biodefense vaccines against plague, and more generally offer clues to controlling excessive inflammatory responses in arthritis, heart and lung diseases, colitis and autoimmune disorders.
Source: EurekAlert! - Social and Behavioral Science - December 13, 2012 Category: Global & Universal Source Type: news

Scientists find drug that may help in fight against Duchenne muscular dystrophy
Drugs that are currently being tested show promise for treating patients with Duchenne muscular dystrophy, an inherited disease that affects about one in 3,600 boys and results in muscle degeneration and, eventually, death. Now, scientists at UCLA have identified an additional drug — one that is already approved by the U.S. Food and Drug Administration and is being used in humans — that provides a powerful boost to the therapy now being tested in clinical trials. They ho...
Source: UCLA Newsroom: Health Sciences - December 12, 2012 Category: Universities & Medical Training Source Type: news

Pupils present results from their own scientific studies into arthritis and cancer
School pupils in Bristol who have been undertaking ‘real’ research into genes linked to arthritis and cancer as part of a new scheme that aims to engage students in science will be presenting their findings at a conference next week [17 Dec].
Source: University of Bristol news - December 12, 2012 Category: Universities & Medical Training Authors: news_text Tags: Press releases Source Type: news